JAMA Current Issue

FDA Approval of Obecabtagene Autoleucel for B-Cell Acute Lymphoblastic Leukemia

This JAMA Insights discusses the recent FDA approval of obecabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia and provides regulatory considerations.

Apr 15, 2025 - 16:45
 0
This JAMA Insights discusses the recent FDA approval of obecabtagene autoleucel for adults with relapsed or refractory B-cell acute lymphoblastic leukemia and provides regulatory considerations.
Read More

Tags:

Previous Article

Semaglutide Shows Promise in Reducing Alcohol Cravings

Next Article

Study: Bleeding Risk With Some Blood Thinners Similar to Aspirin

Related Posts

Emergency Clinician Buprenorphine Initiation and Prescr...

Apr 8, 2025  0

Testicular Germ Cell Tumors

Mar 4, 2025  0

Cognitive Behavioral Therapy Approach May Improve Long ...

Feb 18, 2025  0